Related Experiment Video
Updated: May 24, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Pharmacist-led standardized intervention framework improves LDL-C goal attainment in lipid-lowering therapy: A
Dong-Yan Chai1, Hong-Ye Han2, Chengyang Xu3
1Department of Pharmacy, Henan provincial people's hospital, Zhengzhou University People's Hospital; Henan University People's Hospital, Zhengzhou, Henan, China (Chai, Han, and Wang); International Medical Center of Henan Province, Henan provincial people's hospital, Zhengzhou, Henan, China (Chai, Xu, and Liu).
Journal of Clinical Lipidology
|May 22, 2026
Summary
A pharmacist-led intervention significantly improved low-density lipoprotein cholesterol (LDL-C) goal attainment in high-risk patients in China. This framework enhances lipid management and facilitates the use of nonstatin therapies.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Suboptimal low-density lipoprotein cholesterol (LDL-C) target attainment is prevalent in China, affecting 73.4% of high-risk patients.
- Pharmacists play a key role in lipid management, yet standardized interventions are lacking.
Purpose of the Study:
- To assess the efficacy of a comprehensive pharmacist-led intervention framework in improving LDL-C goal achievement.
- To compare the intervention against usual care in a randomized controlled trial.
Main Methods:
- An open-label randomized controlled trial (RCT) involving 123 adults with elevated LDL-C.
- Participants were randomized 1:1 to a 4-step pharmacist-led intervention or usual care.
- The primary endpoint was LDL-C target attainment at 12 months.
Main Results:
- The pharmacist-led intervention group showed significantly higher LDL-C goal attainment (45.5% vs. 25.9%, P = .033).
- Greater LDL-C reduction was observed in the intervention group (-0.67 mmol/L vs. -0.08 mmol/L, P < .001).
- Adoption of lipid-lowering drugs, particularly non-statins, was significantly higher in the intervention group.
Conclusions:
- The pharmacist-led intervention framework effectively improves LDL-C target attainment in high-risk patients.
- This intervention promotes the uptake of nonstatin therapies and offers a scalable model for integrating pharmacists into cardiovascular care.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...